9998 �� 0.0102. The LOD and LOQ were 20.33 and 60.72 ng/band, respectively. The proposed HPTLC methods were validated for sellckchem intra and interday variations. The values of percent relative standard deviations (RSDs) were found to be 0.76 and 0.94, respectively which indicate that the method was precise. The method was also evaluated by the assay of commercially available tablets containing mycophenolate mofetil. Six replicate analyses were performed on accurately weighed amount of tablets. The percent assay was found to be 99.29 �� 0.77 for mycophenolate mofetil. To study the accuracy of the method, recovery studies were performed. For mycophenolate mofetil, the recovery ranged from 99.26 to 100.5%, with values of percent RSD ranging from 0.29 to 0.72, indicating that the proposed HPTLC method was highly accurate [Table 1].

When the specificity of the method was checked, it was found that the Rf and UV spectrum of the drug standard were the same as those from the sample. The study of robustness of the method revealed that the peak areas were unaffected (RSD < 2%) by small changes in the operating conditions, and can be inferred to be more robust. The method validation parameters are presented in Table 2. Figure 2 Typical HPTLC densitogram of mycophenolate mofetil standard (Rf: 0.55 �� 0.02) Figure 3 Typical HPTLC densitogram of mycophenolate mofetil extracted from tablet formulation (Rf: 0.55 �� 0.02) Table 1 Results from recovery studies of mycophenolate mofetil Table 2 Method validation parameters of mycophenolate mofetil CONCLUSION The developed HPTLC technique is precise, specific, and accurate.

Statistical analysis proves that the method is suitable for the analysis of mycophenolate mofetil as bulk drug and as formulation without interference from its excipients. It may be extended for the quantitative estimation of the said drug in plasma and other biological fluids. ACKNOWLEDGMENT The authors wish to thank Intas Pharmaceuticals Ltd., Ahmedabad, for providing the gift sample of mycophenolate mofetil. They are also grateful to the management of the Hindu College of Pharmacy for providing Drug_discovery the necessary facilities to carry out this project. Footnotes Source of Support: Nil Conflict of Interest: None declared.
Cefpodoxime proxetil is an orally-absorbed prodrug of cefpodoxime, an extended-spectrum, semi-synthetic cephalosporin developed by Sankyo Co. Ltd Japan. Cefpodoxime proxetil, chemically a relatively new broad-spectrum third-generation cephalosporin, has very good in vitro activity against Enterobacteriaceae, Hemophilus spp., and Moraxella spp., including fl-lactamase producers and many strains resistant to other oral agents. It also has activity against gram-positive bacteria, especially against streptococci.